Mescaline-FLY

Mescaline-FLY is not known to have been tested in humans, and hence it is unknown whether it produces psychedelic effects in humans. However, based on its lack of psychedelic-like effects in animals, it may not be expected to be hallucinogenic in humans. ==Pharmacology==

Pharmacodynamics Mescaline-FLY shows affinity for the serotonin 5-HT2 receptors. Hence, whereas mescaline is a full agonist of the serotonin 5-HT2A receptor, mescaline-FLY is a moderate-efficacy partial agonist of the receptor. The lack of substitution with mescaline-FLY is in notable contrast to findings with other FLY drugs, such as 2C-B-FLY, DOB-FLY, and Bromo-DragonFLY. ==History==

Mescaline-FLY was first described in the scientific literature by the lab of David E. Nichols and colleagues by 1995. ==Society and culture==

Legal status Canada Mescaline-FLY is not a controlled substance in Canada as of 2025. United States Mescaline-FLY is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. ==See also==